compensated cirrhosis.
Multi organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging
... Background and Aims: Advancing liver disease results in deleterious changes in a number of critical organs. The ability to measure structure, blood flow and tissue perfusion within multiple organs in a single scan has ...
51
MRI assessment of altered dynamic changes in liver haemodynamics following a meal challenge in compensated cirrhosis
... tissue perfusion and oxygenation in both healthy partici- pants and patients with CC following a test meal. Base- line serum levels, ELF scores and LSM are in line with those reported in the literature for healthy ...
11
Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
... Results: Two hundred forty-two CHB-related compensated cirrhosis patients from 2008 June to 2011 December were included in our study. One hundred twenty-seven patients received anti-virus regimen containing ...
5
Successful treatment of chronic hepatitis C virus genotype 1b infection of a patient with compensated cirrhosis after renal transplantation using daclatasvir-asunaprevir combination therapy: a case report and literature review
... dysfunction, cirrhosis, and hepatocellular carcin- oma, and the target of the therapy is elimination of the virus ...for compensated cirrhosis due to HCV genotype 1b infection after ...
6
Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study
... Our study demonstrated that anti-virus regimen con- taining ADV provide a lower probability of HCC devel- opment than regimen without ADV in CHB related compensated cirrhosis patients. It has been ...
6
Progression of liver stiffness predicts clinical events in HIV/HCV coinfected patients with compensated cirrhosis
... to the caring physician criteria and the availability at each hospital. However, the great majority of patients were monitored at a minimum every 12 months and more than one half of the patients were monitored every 6 ...
8
Evaluation of the prevalence of minimal hepatic encephalopathy in patients with compensated cirrhosis
... This is to certify that the Dissertation entitled “EVALUATION OF THE PREVALENCE OF MINIMAL HEPATIC ENCEPHALOPATHY IN PATIENTS WITH COMPENSATED CIRRHOSIS” here with submitted by Dr. T.YOGANANDH, Post ...
78
HEPATIC ENCEPALOPATHY IN ILLETERATE PATIENTS WITH COMPENSATED CIRRHOSIS
... with compensated cirrhosis (no ascites, overt encephalopathy, variceal bleeding or jaundice) with F4 Score on Shear-wave Elastography were selected for study after informed ...
5
Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
... a phase 3, double-blind, placebo-controlled 12-week study involving 624 chronic HCV patients from across the globe representing genotypes 1, 2, 4, 5, and 6. Patients were ran- domly assigned to the treatment group (a ...
6
<p>Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy</p>
... without cirrhosis (8 weeks of treatment) or with compensated cirrhosis (12 weeks of treat- ment), and for patients with HCV GT 1 infection, who previously have been treated with an NS5A inhibitor or ...
13
Liver Transient Elastography Combined to Platelet Count (Baveno VI) Predict High Esophageal Varices in Black African Patient with Compensated Hepatitis B Related Cirrhosis
... related cirrhosis on the Baveno VI ...diagnosing compensated cirrhosis, gastroscopy screening for EV could be ...of cirrhosis based on ...
9
<p>Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C</p>
... Bacon et al examined the accessibility and utilization of SOF/ VEL/VOX in practice, focusing on patients with a history of treatment failure with an NS5A inhibitor-containing HCV regimen. 34 Data for this study were ...
10
The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis
... with cirrhosis and clinically normal renal function (hepatology 2001; A ...pensated cirrhosis (P < ...with compensated cirrhosis and these changes persist up to 3 hours after ...
7
A New Biomarker for Hepatocellular Damage: Plasma Cell Free DNA
... Hepatorenal syndrome (HRS) is a fatal complication of de- compensated cirrhosis. HRS may be manifested as impaired renal function, ascites and edema. Sodium retention plays a fundamental role in the ...
7
Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive care unit
... of cirrhosis [36], and cirrhotic patients in ICUs have higher risks of sepsis and death, particularly in end-stage liver disease ...in compensated cir- rhotic patients with severe sepsis in ICUs, but the ...
9
Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt
... with compensated cirrhosis, orders of magnitude for probabilities are around 1 percent and sometimes 1 per mile, and overestimations are clearly accentuated for such a ...
9
Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications
... patients): compensated cirrhosis; group II (10 patients): cirrhosis with gastrointestinal hemorrhage due to portal hypertension; group III (10 patients): cirrhosis with hepatorenal syndrome; ...
7
Liu_unc_0153D_16154.pdf
... sample. We focused on density of PCPs, GI/ENDOs, and other physicians. MarketScan contain enrollees’ five-digit Federal Information Processing Standard (FIPS) codes between year 2000 and 2010, but the variable was then ...
110
Antimicrobial Pharmacotherapy of Community-acquired Pneumonia in Liver Cirrhosis Patients: Accent on the Antibiotic Resistance Risk Stratification
... and cirrhosis of the liver of alcoholic etiology were ...with cirrhosis of the liver of mixed alcohol-viral etiology, the following microorganisms prevailed: ...with cirrhosis) differ depending on ...
7
A PROSPECTIVE OBSERVATIONAL STUDY ON EVALUATION OF EFFECT OF PATIENT COUNSELLING BY CLINICAL PHARMACIST IN IMPROVING MEDICATION RECONCILIATION IN PATIENTS WITH CIRRHOSIS AT A TERTIARY CARE HOSPITAL
... leading cause of death overall and the fifth leading cause of death for patients aged 45 to 54 yrs. [3] The progression to cirrhosis is very variable and may occur over weeks or many years. Around 80-90% of the ...
13